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Abstract
Background: Weight gain is commonly observed during psychotropic treatments for chronic
forms of severe mental illness and is most rapid during the early treatment phases. All formats of
behavioural weight intervention programmes have suggested that weight gain can be prevented or
reversed in some patients. There is no data on these programmes in acutely unwell inpatients
whom may be the major beneficiaries.
Methods: A modular behavioural intervention programme (Solutions for Wellness) used in SMI
outpatients since 2002 in Ireland has been adapted for inpatient use. Preliminary data is reported
from 5 centres in Ireland.
Results: In 47 inpatients the mean weight change was +0.26 kg (SD 2.02) with a median change of
0 kg. Mean follow-up was 23.7 (SD 21.6) days, and median 14 days (range 6–98 days). There was
no difference in mean weight change in those patients involved for > 35 days compared with < 35
days (+0.26 kg; 0.25 kg; p = 0.5). Weight loss or maintenance was seen in 70% of patients.
Conclusion: These preliminary data are supportive of the concept that acutely unwell inpatients
with SMI may engage with a behavioural weight programme. Weight change observed contrasts
with the significant weight gain often seen in most subjects. Further clinical trials are warranted.
Background
There has been increasing recognition that cardiovascular
mortality is significantly increased in patients with severe
mental illness (SMI) [1-3]. There are complex reasons for
this that include genetic predisposition, smoking, poor
dietary choices, decreased physical activity and weight
gain observed with most psychotropic treatments [4]. The
consensus view is that cardiovascular risk factors in SMI
patients need to be reduced [2,5]. Weight gain prevention
is one of the more easily defined and measured problem
areas.
Patients with schizophrenia are generally of normal BMI
at illness onset and males may even be underweight [6].
Published: 15 September 2008
BMC Psychiatry 2008, 8:76 doi:10.1186/1471-244X-8-76
Received: 29 February 2008
Accepted: 15 September 2008
This article is available from: http://www.biomedcentral.com/1471-244X/8/76
© 2008 Bushe et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Psychiatry 2008, 8:76 http://www.biomedcentral.com/1471-244X/8/76
Page 2 of 5
(page number not for citation purposes)
There is clear recognition that patients treated in their
early phase of psychosis gain significant weight during the
first year of treatment with the recent CAFÉ study report-
ing 80% olanzapine subjects, 50% quetiapine and 58%
risperidone subjects gaining > 7% of their body weight in
the first 12 months [7] in the absence of any preventative
intervention. In addition although weight gain is maximal
during the early months of initiating antipsychotic treat-
ment, in a large 3 year naturalistic study an increasing
number of subjects on all medications continued to gain
weight during the 3 year study [8,9], and [10].
These efficacy based clinical trials both randomised and
observational have to date not been able to encompass
any preventative measures to reduce weight gain. Despite
this a variety of weight and lifestyle management pro-
grammes have been developed worldwide in outpatients
and broadly have produced good results [11-16]. The
forms of intervention range from weekly group sessions
using behavioural models through to one to one nursing
sessions and telephone/internet based models [17].
In Ireland a lifestyle management programme Solutions for
Wellness has been operating in outpatients with forms of
severe mental illness (SMI) since 2002 and recently
reported preliminary data in the outpatient subject cohort
[15]. The programme has been slightly adapted to be used
in an inpatient setting with the rationale of earlier inter-
vention. We describe preliminary results from the initial
cohort of patients evaluated. The premise being evaluated
is that early weight gain may be prevented or reduced in
some patients.
Methods
A group programme (Acute Solutions for Wellness)
designed to address weight and other cardiovascular risk
factors commenced in 2005 in a number of geographi-
cally diverse centres in Ireland in inpatients with acute
forms of severe mental illness (SMI). Five centres of those
taking part in the programme agreed to provide their data
for a preliminary service evaluation. Data was not rou-
tinely recorded in other centres. There was no restriction
placed on the precise diagnoses to which the intervention
would be offered to but it was expected that most patients
would have schizophrenia or severe affective disorders
and was offered to suitable inpatients referred by the ward
nursing staff. There was neither restriction on drug and
non-drug treatments nor age restrictions. As this was not a
clinical study total discretion for entry to the programme
remained with the ward nursing staff. They chose subjects
whom they considered were potentially suitable for the
programme based on mental state. The groups com-
menced with a cohorts of patients at each centre whom
progressed through the programme sequentially as a
group.
The programme consisted of 8 modules to complete over
4 weeks, each module of 30 minutes covering dietary
choices, appetite, physical activity and nutrition. The
materials were adapted to be simplified from the outpa-
tient version of the same service and in addition modules
were designed to be 30 instead of 60 minutes each. The
programme otherwise was unchanged. Groups were led
by trained healthcare professionals usually nurse. The
nurses received full training in the operation of the mod-
ular programme and worked from identical source mate-
rial workbooks consisting of 20 page instructor guides
describing each module individually. Patients also
received written materials in the form of a 22 page work-
book similarly describing in appropriate terminology
each module separately. The 8 modules covered the top-
ics:
1. Healthy living
2. Physical activity
3. The food pyramid
4. Recommended food servings
5. Fat and salt in your diet
6. Healthy and unhealthy eating habits
7. High fibre diet
8. Controlling your hunger
The patients received either twice weekly modules each 30
minutes or a single hourly session weekly combining two
modules. Subject diagnoses were recorded from the notes.
Ethics
Ethical approval was not sought as this service provision
of SFW was deemed to be part of good clinical practice
and service evaluations may be considered exempt from
ethical review. The only difference being that the service
was provided in secondary care rather than in primary
care. Informed consent was obtained from the patients to
use their data in an anonymised manner for the purpose
of a service evaluation.
Statistical Analysis
Our analysis has been predominantly descriptive, aiming
to present the raw data as a series of weight or BMI results
over a period of time. Our descriptive statistics are sup-
ported with standard deviations, median and significance
is reported where appropriate.BMC Psychiatry 2008, 8:76 http://www.biomedcentral.com/1471-244X/8/76
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Results
Since 2005 data is available from 47 patients (26 females,
21 males) from 5 centres. Diagnoses were Schizophrenia
in 17/47, affective disorders 25/47, non-psychotic diag-
noses (personality disorder, anxiety, alcohol misuse) 5/
47. Baseline mean weight 78.4 kg (SD 15.2 kg) and
median 77 kg (range 47–135 kg).
The mean weight change was +0.26 kg (SD 2.02) with a
median change 0 kg. Paired Student's t-Test t = -0.624, df
= 46, p = 0.950. Mean follow-up 23.7 (SD 21.6) days,
median 14 days (range 6–98 days) with 16/47 engaging
with the programme >=21 days (figure 1). The categorical
weight changes at discontinuation with programme were
weight gain in 14/47 (30%), weight maintenance in 21/
47 (45%) and weight loss in 12/47 (25%). The categorical
changes are shown in figure 2. The mean weight change in
the 10/47 patients whom remained in the programme
>=35 days was +0.25 kg, (SD 3.55) and in the 37/47
whom remained in the programme <=35 days +0.262 kg,
(SD 1.43) (p = 0.50)
Discussion
In this preliminary report an adapted lifestyle interven-
tion programme has found promising results. At discon-
tinuation of engagement with the programme only 14/47
(30%) patients had gained weight during a mean follow
up of 24 days (median 14 days) and the remainder either
maintained their weight or lost weight. The median
weight change was 0 kg. Furthermore there were no differ-
ences between those patients who remained in the pro-
gramme less than 35 days compared to the group whom
engaged for greater than 35 days (p = 0.5). These data may
hold relevance in that a major determinant of length of
engagement with SFW was the time to discharge of the
patients. At discharge there would be no certainty that
continual engagement with any weight management of
lifestyle intervention programme would be either offered
or accepted.
There are few data which can be compared with our data
as to our knowledge this is one of the first data sets that
has examined a lifestyle intervention in an inpatient SMI
cohort acutely unwell.
Some short term interventions have been successful in
outpatients. In a 14-week open label study of patients
switched to risperidone from olanzapine and randomised
to receive a behavioural intervention, 27% of the active
cohort lost > 5% body weight over 14 weeks [13] and in a
12-week intervention using a similar programme to Acute
SFW in outpatients there was a mean weight loss of 2.7 kg
[18]. The few studies that have examined interventions in
early phases of illness are worth comparison. A study of
61 first-episode patients aged 16–45 years randomised to
behavioural intervention or "usual care" over 12 weeks
[19]. Only 40.7% of the intervention group gained > 7%
of weight compared with 77% of the control group. Simi-
lar data was reported from a cohort of 50 patients ran-
domised to intervention or usual care within 30 days of
commencement on an antipsychotic and followed for 16
weeks [20]. 63% of the intervention cohort experienced
no weight gain compared with 22% of the control
patients (p = 0.009). In this study 70% of our cohort expe-
rienced no weight gain but only over mean 24 days follow
up. A further encouraging finding was that the patients
engaging with the programme for greater than 35 days
had no greater weight gain than those engaging for less
time. In a recent naturalistic study of an admixture of
inpatients and outpatients (mean weight loss 2.64 +- 2.75
kg) BMI reduction over 12 weeks was greater in the outpa-
Length of engagement with programme by patients Figure 1
Length of engagement with programme by patients.
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tient cohort making these preliminary data even more
encouraging and worthy of further research [21].
The literature on weight management programmes con-
sists primarily of uncontrolled interventions, whose data
seems promising and shorter term controlled trials but
not conclusive of benefit. With a few reservations most
data show encouraging results. A number of systematic
reviews and reviews have consistently suggested some
benefit from these programmes [14,22]. Recent control-
led trials have also suggested more tangible gains from
lifestyle programmes. Mauri et al, report a reduction in
fasting insulin levels, insulin resistance (HOMA index)
and improvement in insulin sensitivity but unchanged
FPG in an olanzapine cohort randomised to a psycho edu-
cational programme for weight loss [23] for either 12 or
24 weeks. Menza found a reduction in glycosylated hae-
moglobin over 1 year using a multi-modal weight control
programme (n = 31) from 5.35% to 5.11% (p = 0.001)
[24].
The data from the UK programme Wellbeing support pro-
gramme report 80% retention in the programme over 2
years and in addition to reduction of various cardiovascu-
lar risk factors; weight gain to any extent was measured in
only 30.8 % [25]. Longer term compliance with these pro-
grammes may be crucial with recent data suggesting com-
pliance is a significant factor [21,11], and [12]. An
additional salient consideration is that Werneke et al in
2002 [26] and Faulkner in 2007 [27] concluded that there
was not sufficient evidence to use any pharmacological
agents for weight reduction or prevention.
In a Cochrane review in 2007 Faulkner found that only 5
trials out of 23 randomised interventions were behav-
ioural in type and modest weight loss and prevention
were reported [27]. The relevant caveats around these
findings included small studies over short term periods
with varying interventions, and longer term larger studies
need to be undertaken before making definitive state-
ments of benefit.
Limitations
There are however significant limitations in our data that
will need to be resolved in future controlled clinical stud-
ies and in further service evaluations of this programme.
Primarily this relates to the nature of this being a service
evaluation and not a form of designed controlled trial or
audit. These data may provide hypotheses for future con-
trolled evaluations of such programmes in acutely unwell
SMI patients. There are no data on the number of patients
who were available for the intervention but were either
not approached or declined. Thus it cannot be certain that
our results can be extrapolated to other inpatient popula-
tions. There is also no data on the severity of the patient's
illness and there is no control group. All data obtained
from this service evaluation has been included, however
data on many demographics including pharmacological
treatments, previous weight changes and BMI were not
available for 38% of the patients and have thus not been
reported. A final limitation is the short follow up period
that fails to assess whether any benefits may persist.
Conclusion
Despite these limitations there is an increasing body of
evidence that weight management interventions may
potentially provide benefit [12,21] although caveats
remain that most studies are small, use varying interven-
tions and are mostly short term. Further clinical studies
are required in acutely psychotic patients to determine if
early weight gain can be prevented or ameliorated and
benefits maintained longer term. Soon after diagnosis of
psychosis and soon after drug initiation in more chronic
subjects, may represent crucial times to intervene with
regard to prevention of weight gain.
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